US warns Endo on sales material for pain patch

	Tweet

Some Endo Pharmaceuticals sales material for the Lidoderm pain patch was misleading because it contained unsupported effectiveness claims and omitted important information about risks, U.S. regulators said in a letter released on Wednesday.

The U.S. Food and Drug Administration told the company to immediately stop distributing two direct mail pieces.

The materials “are false or misleading because they make unsubstantiated effectiveness claims for Lidoderm, they omit and minimize serious risk information associated with use of the drug and they inadequately communicate an important limitation in Lidoderm’s approved indication,” the FDA letter said.

Regulators said the materials left out warnings about wearing the patch for too long and omitted advice on how to store and dispose of the product so that it is out of reach of children and pets, which can be harmed by ingesting a new or used patch.

The company also failed to note that Lidoderm should be applied only to intact skin, not broken or inflamed skin, according to the FDA’s letter.

The sales materials were sent to doctors earlier in 2005 and in 2004, Endo spokesman Bill Newbould said.

“We’re working with the FDA to take corrective action,” he said.

Shares of the Chadds Ford, Pennsylvania-based company fell 3 cents to $25.96 in afternoon trading on Nasdaq. 

RELATED STORIES:
Antipsychotic drug for dementia have adverse effects   No illegal drugs in Winehouse toxicology report   Anesthesiologists Vulnerable to Drug Abuse   Drug reduces hot flashes in breast cancer patients   Malaria preventive linked to ‘psychiatric events’   Medicare prescription drug abuse a problem: GAO   Drug prevents bone loss side effects of breast cancer medication   Dangerous low blood sugar linked to sex drugs   FDA: Power to write drug labels could help public   New pain relievers boost blood pressure more - study   Physicians more worried about drug safety: survey   Eczema drugs carry cancer risk, US FDA says

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]